Literature DB >> 6154083

Preferential H-2 association in cytotoxic T cell responses to SV40 tumor-associated specific antigens.

K Pfizenmaier, S H Pan, B B Knowles.   

Abstract

The primary cytotoxic T lymphocyte (CTL) response to the SV40 tumor-associated specific antigen (TASA) has been analyzed in H-2 recombinant mice of the H-2b,d,f,k,q,and s haplotypes, in F1 hybrid mice (of each combination of these six independent haplotypes), and in intra-H-2 recombinant mice. A gradation of responsiveness to SV40 TASA in association with the various H-2 K/D alleles is reported. A weak response is found in association with the H-2 Dd allele, which is strongly affected by the responder status in association with the other H-2 K/D region determinants of the immunized host. Analysis of CTL from F1 mice, after secondary in vitro restimulation with SV40-transformed cells from either parental strain, indicates that in vivo priming to SV40 TASA in association with each K/D associative allele does occur, although efficient CTL are found only in association with specific H-2 K/D determinants after primary immunization. Mechanisms to explain host control of the ability to generate effector T cells to the TASA of this oncogenic virus are discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6154083

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Rotavirus-specific cytotoxic T lymphocytes cross-react with target cells infected with different rotavirus serotypes.

Authors:  P A Offit; K I Dudzik
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

2.  Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.

Authors:  Devin B Lowe; Michael H Shearer; Cynthia A Jumper; Robert K Bright; Ronald C Kennedy
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

3.  Fine mapping two distinct antigenic sites on simian virus 40 (SV40) T antigen reactive with SV40-specific cytotoxic T-cell clones by using SV40 deletion mutants.

Authors:  R W Anderson; M J Tevethia; D Kalderon; A E Smith; S S Tevethia
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

4.  Requirements for the stimulation of allogeneic T lymphocytes by acute non-lymphoblastic leukaemia cells.

Authors:  L K Ashman; G W Kriek; S J Cooper; D E O'Keefe
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  Inverse relationship between anti-SV40 TASA and anti-H-2 cytotoxic responses.

Authors:  C De Giovanni; S Grilli; P L Lollini; G Nicoletti; G Prodi; P Nanni
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

6.  Immunodominance in the immune response to "multiple" histocompatibility antigens.

Authors:  P J Wettstein; D W Bailey
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

7.  Lack of effect of mouse adenovirus type 1 infection on cell surface expression of major histocompatibility complex class I antigens.

Authors:  S C Kring; K R Spindler
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

8.  CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.

Authors:  Joel F Aldrich; Devin B Lowe; Michael H Shearer; Richard E Winn; Cynthia A Jumper; Robert K Bright; Ronald C Kennedy
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

9.  Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.

Authors:  O Utermöhlen; C Schulze-Garg; G Warnecke; R Gugel; J Löhler; W Deppert
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Tumor induction by simian virus 40 in mice is controlled by long-term persistence of the viral genome and the immune response of the host.

Authors:  J Abramczuk; S Pan; G Maul; B B Knowles
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.